Sales Recouping

GSK to Acquire Rapt Therapeutics for $2.2 Billion to Add Anti‑IgE Food‑Allergy Drug

GSK moves to fortify its immunology pipeline with a mid‑stage anti‑IgE drug that could shift food‑allergy care.